Stock Quote
Onyx Pharmaceuticals Inc (ONXX.W) (NASD ADF)
$28.35
23 Nov 2009
+6.50%
$26.62
$28.35
1,000
$28.35
$28.35
$37.02
$21.85
0.63
904,318
ONXX.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Coles, N. Anthony | President, Chief Executive Officer, Director | 2,770,810 |
| Fust, Matthew | Chief Financial Officer, Executive Vice President, Principal Accounting Officer | -- |
| Brege, Laura | Chief Operating Officer, Executive Vice President | 1,705,190 |
Profile
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing anticancer therapies. The Company’s product, Nexavar (sorafenib) tablets, being... Full Description
Company Address
Onyx Pharmaceuticals Inc
2100 Powell Street
Emeryville CA 94608
P: +1510.5976500
F: +1510.5976600
2100 Powell Street
Emeryville CA 94608
P: +1510.5976500
F: +1510.5976600
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Pfizer Inc. | $18.53 | +0.17 |
| Wyeth | -- | -- |
| ONXX.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 7.47 | 29.90 |
| ROI(TTM) | -1.21 | 2.35 |
| ROE(TTM) | -1.37 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.24 |
| EPS Est. (Current Year) | 0.78 |
| Total Revenue | $69.14M |
| Net Income | $8.23M |
| EPS | $0.14 |
